Pascal Oury

This inventor holds 19 USPTO granted patents and 6 published patent applications, plus 7 CIPO patents and 12 EPO patents, primarily in Pharmaceutical Formulations. Top assignees: Ethypharm, Inc., Laboratoires Des Produits Ethiques Ethypharm, Laboratoires Des Products Ethiques Ethypharm. Active years: 2000-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pascal Oury. Retrieved from https://idiyas.com/inventor/pascal-oury

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 6)

% Patents Active = 84.2

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 5)

Average Co-Inventor Count = 3.9

ph-index = 10

Forward Citations = 216(Granted Patents)

Location History:

Paris, FR (2000 - 2003)
Versailles, FR (2004)
Le Chesnay, FR (2006 - 2018)

Company Filing History:

Laboratoires Des Produits Ethiques Ethypharm

patents

2 out of 2

Laboratoires Des Products Ethiques Ethypharm

Laboratories Des Produits Ethiques Ethypharim

patent

6. 1 out of 1

Laboratories Des Produits Ethiques Ethypharm

patent

Years Active: 2000-2018

Loading Chart...

Areas of Expertise:

Opioid Compositions

Microgranules

Sustained-Release Tablets

Orally Disintegrating Tablets

Thin Film Formulations

Coated Granules

Buccal Delivery

Pharmaceutical Preparations

Gastroprotected Microgranules

Spheroids

Fentanyl Tablets

Fenofibrate

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10111869 - Reduction of opioid blood fluctuations (2018-10-30),

2. 9603797 - Oral and/or buccal composition in the form of a thin film of a weakly soluble active ingredient, method of preparing same and use of same (2017-03-28),

3. 8709479 - Sublingual coated tablet of fentanyl (2014-04-29),

4. 8603525 - Multilayer orally disintegrating tablet (2013-12-10),

5. 8529952 - Pharmaceutical composition containing fenofibrate and method for the preparation thereof (2013-09-10),

6. 8501160 - Crush-resistant oxycodone tablets intended for preventing accidental misuse and unlawful diversion (2013-08-06),

7. 8409612 - Microgranules insoluble in gastric fluid, method for obtaining same and pharmaceutical preparations (2013-04-02),

8. 8263126 - Orally-dispersible multilayer tablet (2012-09-11),

9. 7863331 - Pharmaceutical composition containing fenofibrate and method for the preparation thereof (2011-01-04),

10. 7063864 - Morphine sulphate microgranules, method for preparing same and compositions containing same (2006-06-20),

11. 6770298 - Device for coating granules to be administered orally (2004-08-03),

12. 6660296 - Sustained-release microgranules containing diltiazem as active principle (2003-12-09),

13. 6551621 - Gastroprotected omeprazole microgranules, method for obtaining same and pharmaceutical preparations (2003-04-22),

14. 6482437 - Morphine sulfate microgranules, manufacturing process and pharmaceutical preparations (2002-11-19),

15. 6458389 - Microgranules containing cisplatin (2002-10-01),

Title: Innovations and Contributions of Pascal Oury in Pharmaceutical Patents

Introduction

Pascal Oury, based in Le Chesnay, France, is a notable inventor with a strong patent portfolio that includes 19 patents. His inventions primarily focus on advancements in pharmaceutical formulations, particularly involving opioids and delivery methods for active ingredients.

Latest Patents

Among his latest innovations, one significant patent addresses the “Reduction of opioid blood fluctuations.” This invention is related to a sustained release matrix containing at least one opioid, designed to produce a solid oral formulation in tablet form that effectively reduces blood concentration fluctuations of the opioid. Another notable patent revolves around an “Oral and/or buccal composition in the form of a thin film.” This patent details a composition with weakly soluble active ingredients formulated as a thin film, comprising particles dispersed in a film-forming polymer, with specific particle size distributions aimed at enhancing bioavailability.

Career Highlights

Pascal Oury has made significant contributions to the pharmaceutical field through his work at prominent companies. He has been associated with Ethypharm, Inc. and Laboratoires Des Produits Ethiques Ethypharm, where he played a key role in the development of several innovative pharmaceutical solutions.

Collaborations

Throughout his career, Oury has collaborated with notable colleagues, including Pascal Suplie and Patrice Debregeas. These partnerships have likely contributed to the depth and breadth of his research and development efforts, leading to his successful patent applications.

Conclusion

Pascal Oury's work in developing novel pharmaceutical formulations has enriched the field of medicine. His contributions, particularly in the realm of opioid management and advanced drug delivery systems, highlight his commitment to innovation and his role as a key figure in the industry. As he continues to innovate, Oury’s patents will likely pave the way for future advancements in pharmaceutical science.

Profile summary based on public USPTO records.